Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan D Richman

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Histopathology|May 8, 2019
Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trialPaul Barrow, Susan D Richman, Andrew J Wallace, et al.
Journal of Clinical Pathology|September 10, 2015
Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trialSusan D Richman, Richard Adams, Phil Quirke, et al.
JAMA Oncology|October 28, 2017
Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal CancerJenny F Seligmann, Ace J Hatch, Susan D Richman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trialMichael S Braun, Susan D Richman, Lindsay Thompson, et al.
Molecular Cancer Research : MCR|January 3, 2025
Coevolution of Atypical BRAF and KRAS Mutations in Colorectal TumorigenesisConnor E Woolley, Enric Domingo, Juan Fernandez-Tajes, et al.
Journal of Clinical Pathology|March 8, 2022
FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testingSusan D Richman, Gemma Hemmings, Helen Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trialMichael S Braun, Susan D Richman, Philip Quirke, et al.
Molecular Oncology|July 17, 2020
A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironmentAmélie Viratham Pulsawatdi, Stephanie G Craig, Victoria Bingham, et al.
The Journal of Pathology|February 8, 2018
Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsiesMatthew Alderdice, Susan D Richman, Simon Gollins, et al.
Clinical Trials (London, England)|January 27, 2022
Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancerLouise C Brown, Janet Graham, David Fisher, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Histopathology|May 8, 2019
Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trialPaul Barrow, Susan D Richman, Andrew J Wallace, et al.
Journal of Clinical Pathology|September 10, 2015
Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trialSusan D Richman, Richard Adams, Phil Quirke, et al.
JAMA Oncology|October 28, 2017
Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal CancerJenny F Seligmann, Ace J Hatch, Susan D Richman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trialMichael S Braun, Susan D Richman, Lindsay Thompson, et al.
Molecular Cancer Research : MCR|January 3, 2025
Coevolution of Atypical BRAF and KRAS Mutations in Colorectal TumorigenesisConnor E Woolley, Enric Domingo, Juan Fernandez-Tajes, et al.
Journal of Clinical Pathology|March 8, 2022
FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testingSusan D Richman, Gemma Hemmings, Helen Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trialMichael S Braun, Susan D Richman, Philip Quirke, et al.
Molecular Oncology|July 17, 2020
A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironmentAmélie Viratham Pulsawatdi, Stephanie G Craig, Victoria Bingham, et al.
The Journal of Pathology|February 8, 2018
Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsiesMatthew Alderdice, Susan D Richman, Simon Gollins, et al.
Clinical Trials (London, England)|January 27, 2022
Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancerLouise C Brown, Janet Graham, David Fisher, et al.
Pageof 5